Lumin UV System for Use in Nursing Homes, Ambulatory Care and Primary Care for SARS-CoV-2 N95 Re-Use Is Granted 3B Medical Emergency Use

December 4, 2020

Lumin UV system, has received Emergency Use Authorization from the FDA to permit use of the system, on N95 respirators during the COVID-19 pandemic.

Lumin UV system was designed to clean CPAP accessories but is also used as a multi-purpose sanitizer. Today’s announcement by the FDA allows Lumin to be used by healthcare workers employed in nursing homes, long term acute care, ambulatory, primary care, and clinics to allow N95 re-use to stop the spread of COVID-19 and help keep frontline healthcare workers safe.

UVC was first reportedly used for N95 decontamination during the COVID-19 crisis by the University of Nebraska Medical Center. Since then the CDC recognized UVC as a potential means of decontaminating N95 respirators if the proper wavelength and UVC irradiance dose were used. While the FDA has approved other systems for hospital use, the approved systems are complicated, limited to large hospitals, and/or extremely expensive. Lumin is the only N95 decontamination system formally recognized by FDA for killing SARS-CoV-2 that can be purchased for under $300, and with a small enough footprint to be used safely in small offices and clinics, as well as in nursing homes.

Alex Lucio, CEO of 3B Medical, Inc., said, “The COVID-19 global pandemic requires novel approaches and thinking outside the box.  We were starting to get inundated with calls from hospitals and nursing homes asking if Lumin was strong enough to kill SARS-CoV-2. Lumin’s total output in a single 5-minute cycle ranges up to  2,400 mJ/cm2, which studies show is sufficient to kill almost any pathogen, including SARS-CoV-2. A lot of the calls coming into our office are from Fire & Rescue departments, nursing homes, and smaller community hospitals, clinics, and primary care physician offices trying to keep their workers safe.”

He added, “Lumin is likely the only device designed for home use that is powered high enough to repurpose for this use. We are very excited to have our device authorized by FDA for this application”, concluded Lucio.

N95 mask shortages have been widely reported throughout the country, and globally. “Being able to re-use an N95 mask quickly and effortlessly is a game-changer for allowing healthcare workers to remain safe.  Front line healthcare workers are in dire need of an immediate solution to re-use their masks.  Lumin is fast and easy to use and we are glad the device could be re-purposed to meet that need in this crisis,” said Lucio.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”